source
- Roche licenses Rona's ALK7 obesity candidate in $1.2 billion dealRoche has agreed to license an RNAi drug candidate targeting ALK7 from Chinese biotech Rona Therapeutics, with an upfront payment of $100 million and potential milestones up to $1.06 billion. The…
- Verdiva Bio halts mid-stage obesity trial of its GLP-1 pill, citing market evolutionVerdiva Bio, a well-funded private biotech, announced it has terminated one of its Phase 2 trials for its lead oral GLP-1 obesity candidate. The company said the decision reflects a shift in the m…